Glaukos (NYSE:GKOS) touted data today from a Phase II trial of its travoprost intraocular implant in a 12-month cohort of glaucoma patients. The company’s iDose device is placed during a micro-invasive procedure and filled with a special formulation of travoprost – a drug used to reduce intraocular pressure. The implant continuously delivers therapeutic levels of travoprost […]
Featured
At confirmation hearing for Trump’s HHS nominee, drug pricing takes center-stage
Alex Azar, the president’s nominee to head the Dept. of Health & Human Services, has nearly a decade of experience in the pharmaceutical industry – and that experience is either predictive of his inability to act on lowering drug prices or will serve him well as HHS chief, depending on who you ask. At Azar’s […]
FDA approves clinician app for Medtronic’s SynchroMed II drug pump
The FDA has approved a new clinician application for Medtronic‘s (NYSE:MDT) SynchroMed II intrathecal drug pump. The newly-approved programmer was designed to give doctors visual tools and improved workflows to simplify therapy management. The medtech titan’s implantable pump, which has been problematic in the past, delivers drugs directly to the fluid around the spinal cord. […]
Wacker wins FDA nod to manufacture active ingredient in Chiesi’s thrombolysis drug
Wacker Biotech said today that it won FDA approval to start producing reteplase, the active ingredient in Chiesi‘s thrombolysis drug, Retavase. The medication, which is designed to treat acute myocardial infarction in adults, will be marketed in the U.S. by Chiesi and made in Wacker’s Germany-based plant. Wacker reported that it landed approval to commercially […]
Metavention raises $65m to tackle diabetes with metabolic neuromodulation therapy
Metavention said today that it closed a $65 million Series C round with funding from New Enterprise Associates, Sanderling Ventures and others. The medical device maker plans to use the funds to optimize its transcatheter-based metabolic neuromodulation therapy for people with Type II diabetes and prepare it for a Phase II trial in the U.S. […]
Novo Nordisk’s once-weekly diabetes injection cleared in Canada
Health Canada has approved Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide injection as an adjunct to diet and exercise that can help adults with Type II diabetes control their blood sugar levels. The drug, Ozempic, is a GLP-1 receptor agonist and won FDA approval in the U.S. in December. “Many of our patients with Type II diabetes […]
Dexcom posts cautious 2018 forecast despite Street-beating Q4, FY17 prelims
Dexcom (NSDQ:DXCM) shares fell today after the company issued conservative guidance for its expected revenue in 2018. The company also posted Street-beating preliminary results for its fourth quarter and full-year 2017 revenues. The company is facing competition in the new year after the FDA approval of Abbott‘s (NYSE:ABT) continuous glucose monitor, the FreeStyle Libre. But chief executive […]
Ascensia inks global distro sale with Insulet for blood glucose monitor
Ascensia Diabetes Care has expanded its partnership with Insulet (NSDQ:PODD) to include a global commercial deal. The two companies inked a world-wide development agreement in June last year to connect Ascensia’s Contour Next One blood glucose monitor with Insulet’s next-gen Omnipod system, Omnipod Dash. According to the terms of the non-exclusive commercial deal, Insulet plans to distribute […]
Allergan talks taxes and competition in 2018 outlook
Allergan (NYSE:AGN) had a busy, and occasionally fraught, 2017. After the company inked a controversial deal with a Native American tribe to shield its Restasis patents from review, a federal judge in Texas invalidated the IP, helping to clear the way for generics. And just last week, Allergan announced that it would slash 1,400 jobs in […]
Novocure revenues climb in Q4, FY17 prelims
Novocure (NSDQ:NVCR) shares rose slightly this morning after the cancer-treatment developer reported its preliminary fourth quarter and full-year revenues. The St. Helier, N.J.-based company said it expects to land $53.7 million in net revenue for the fourth quarter of 2017, up 77% from the same period last year. For the full year, Novocure anticipates it will […]